COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Novel Therapies in Head and Neck Cancer: Beyond the Horizon - 1st Edition - ISBN: 9780128206799, 9780128209295

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume 9

1st Edition

0.0 star rating Write a review
Editors: Maie St. John No Park
Hardcover ISBN: 9780128206799
eBook ISBN: 9780128209295
Imprint: Academic Press
Published Date: 29th June 2020
Page Count: 266
Sales tax will be calculated at check-out Price includes VAT/GST
135.00
175.00
148.75
155.00
280.91
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Chemotherapy: What we have learned from Trials and where are we heading
    2. Chemotherapy: The resistant Setting 3. HPV+ SCCA: Novel approaches
    4. Immunotherapy: Where and when
    5. Radiation: De-escalation
    6. Immunotherapy and Chemotherapy: When two is better than one
    7. Targeted Therapy: The future of Precision
    8. Rare Diseases in Head and Neck: New Approaches
    9. Skin Cancers: Beneath the surface
    10. The Promise of tomorrow: Novel Drug Delivery Platforms

Description

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented.

This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients.

Key Features

  • Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types
  • Discusses the application of immunotherapy to treat rare types of head and neck cancer
  • Presents updated information on targeted therapies, specifically focusing on skin cancer in the region

Readership

Cancer researchers, medical scientists, clinicians, graduate students


Details

No. of pages:
266
Language:
English
Copyright:
© Academic Press 2020
Published:
29th June 2020
Imprint:
Academic Press
Hardcover ISBN:
9780128206799
eBook ISBN:
9780128209295

Ratings and Reviews


About the Editors

Maie St. John

A highly renowned surgeon, scientist and educator, Dr. St. John is Professor and Chair of Department of Head and Neck Surgery and Professor of Bioengineering at UCLA. She also holds the Thomas C. Calcaterra, M.D., Chair in Head and Neck Surgery and is Co-Director of the UCLA Head and Neck Cancer Program. Dr. St. John’s laboratory studies the mechanisms of tumor progression and metastasis in head and neck cancer and seeks to identify and study novel genes and pathways for future targeted therapies, while actively incorporating the results of their laboratory-based research into the development of novel therapeutics. Her extramurally-funded research portfolio includes multiple NIH grants bridging basic science with clinical research and service. Dr. St. John is an outstanding educator who has provided mentorship to numerous trainees, and serves as a member of several prestigious organizations including the Executive Council of the American Head and Neck Society, Nominating Committee of the Triological Society, American Academy of Otolaryngology-Head & Neck Surgery, American College of Surgeons Board of Governors Advisory Council, and American Laryngological Association. She also is a senior examiner for the American Board of Otolaryngology and a reviewer for the American Academy of Otolaryngology/Head and Neck Surgery CORE grants, and NIH/NIDCR, NCI and NIBIB study sections. She has been the recipient of multiple awards for teaching and research. Dr. St. John received her undergraduate degree from Stanford University and both M.D. and Ph.D. degrees from Yale University. She completed residency and postdoctoral training at UCLA. In addition to maintaining a busy surgical practice, Dr. St. John is active in clinical research and is closely involved in training young physician-scientists. Dr. St. John’s clinical expertise is in intraoperative tumor margin delineation in the resection and treatment of head and neck cancers to allow for precision surgery. Her laboratory research is translational with a focus on improving therapies and outcomes for patients with head and neck cancer. Her efforts have helped in the development of strong interdepartmental research program in Head & Neck Surgery and Bioengineering. This work has led to clinical trials and patent applications, and has been consistently funded by the NIH, charitable foundations, and industry.

Affiliations and Expertise

Thomas C. Calcaterra, M.D., Chair in Head and Neck Surgery Chair and Executive Medical Director, Department of Head & Neck Surgery Professor, Head & Neck Surgery and Bioengineering Co-Director, UCLA Head and Neck Cancer Program Associate Director Cancer Research and Education, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA

No Park

Dr. Park is a prominent scientist in oral and craniofacial research, with more than 180 scientific publications in distinguished research journals. His major research activities have been in oral (head &neck) cancer and aging research. Dr. Park's contribution to the understanding of the mechanisms of oral cancer development is enormous and resulted in new mode of therapy. In the early stage of his career (1975-1983), Dr. Park developed animal models to evaluate the therapeutic efficacy of antiviral agents and to study the molecular mechanisms of numerous antiviral agents against herpes simplex virus. In later stages of his research career (since 1983), Dr. Park began to investigate the mechanisms of human oral cancer development.

Affiliations and Expertise

Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA and Dean Emeritus and Distinguished Professor of Dentistry, UCLA School of Dentistry